Top Story

PTC Therapeutics boosted by Novartis rights deal for Huntington’s program

PTC Therapeutics boosted by Novartis rights deal for Huntington’s program

03-Dec-2024

|

By Helen Albert

Editor's Choice

We’ve upgraded BioPharmaReporter to give you more of what you love

We’ve upgraded BioPharmaReporter to give you more of what you love

26-Nov-2024

|

By Jess Spiring

Headlines

Spyre Therapeutics launches Phase 1 trials for its extended...

Roche acquires CAR-T developer Poseida Therapeutics for $1.5 billion

Amgen announces positive Phase 2 results for its GLP-1-GIP weight...

BridgeBio wins FDA approval for inherited cardiomyopathy treatment

Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular...

We’ve upgraded BioPharmaReporter to give you more of what you love

→

In focus

Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases

07-Nov-2024 By Larissa Warneck-Silvestrin

An Experienced CDMO Can Be a Differentiator in the Rapidly Growing Biologics Market

Paid for and content provided by Scorpius BioManufacturing

Abzena announces major expansion of its biologics manufacturing facility

31-Oct-2024 By Larissa Warneck-Silvestrin

Notes on compliance: Building the USP 71 sterility testing processes that support USP, EP and JP harmonized methods

Paid for and content provided by Thermo Fisher Scientific

Featured

Insight

Top 10 rare disease pharma sees 10.4% rise in therapy start

By Liza Laws

Top 10 rare disease pharma sees 10.4% rise in therapy start

Bio developments

→

Spyre Therapeutics launches Phase 1 trials for its extended half-life IBD therapy

Spyre Therapeutics launches Phase 1 trials for its extended half-life IBD therapy

03-Dec-2024

By Larissa Warneck-Silvestrin

PTC Therapeutics boosted by Novartis rights deal for Huntington’s program

PTC Therapeutics boosted by Novartis rights deal for Huntington’s program

03-Dec-2024

By Helen Albert

Eisai and Biogen launch Alzheimer’s treatment in South Korea

Eisai and Biogen launch Alzheimer’s treatment in South Korea

02-Dec-2024

By Liza Laws

Partner insightMore →

Internal Standard (IS) Variation Case Studies: Emerging from Three Common IS Challenges

Content provided by WuXi AppTec

ICH M10 Guidance: Harmonization and Modification to Bioanalytical Method Variation

Content provided by WuXi AppTec

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences

Markets & regulation

→

BridgeBio wins FDA approval for inherited cardiomyopathy treatment

BridgeBio wins FDA approval for inherited cardiomyopathy treatment

26-Nov-2024

By Helen Albert

Helen Harrington’s journey: Patience, passion, and problem-solving

Helen Harrington’s journey: Patience, passion, and problem-solving

20-Nov-2024

By Liza Laws

FDA approves first-ever gene therapy to be directly administered to the brain

FDA approves first-ever gene therapy to be directly administered to the brain

19-Nov-2024

By Clara Rodriguez Fernandez

Top 10 rare disease pharma sees 10.4% rise in therapy start

Top 10 rare disease pharma sees 10.4% rise in therapy start

01-Nov-2024

By Liza Laws

Contract manufacturing & logistics

→

Abzena’s advanced drug development showcased at CPHI Milan

Abzena’s advanced drug development showcased at CPHI Milan

01-Nov-2024

By Liza Laws

CRO NovAliX teams with Bruker to advance drug development

CRO NovAliX teams with Bruker to advance drug development

29-Oct-2024

By Liza Laws

Alto Neuroscience’s depression drug trial fails at phase 2

Alto Neuroscience’s depression drug trial fails at phase 2

24-Oct-2024

By Helen Albert

Investors and big pharma no longer avoiding techbio companies

Investors and big pharma no longer avoiding techbio companies

17-Oct-2024

By Jonathan Smith

Expand your knowledge

Industry Newsletters

Choose from regular, topic-based and special edition briefings

Resource centre

Discover cutting edge insight from our partners

Events & webinars

Explore our programme of live & on-demand content